Discovery Eye Foundation
  • Decrease font size
  • Default font           size
  • Increase font size
Clinical Trials for Wet AMD
Clinical trials are the final research phase before a treatment is approved for the general public. Once a drug or treatment has been developed, it is tested in humans through a succession of clinical trials.

Research on treatments starts in the laboratory where scientists work to identify the processes involved. These are called Pre-Clinical studies. Clinical trials begin with Phase I trials, which test the treatment on a small number of people for safety and best dose. Phase II involves several hundred subjects to test for effectiveness. Phase III expands the study to thousands of people in order to confirm effectiveness and monitor safety and side effects. After the drug or treatment has been approved by the Food and Drug Administration (FDA) and made available for public use, studies continue to track side effects and success.

Clinical trials listed below are divided into three time frames. The first are the Clinical Trials that are still "Recruiting" patients to participate in the study. The second are the Trials that are currently in progress, but are "Not Recruiting" new patients. The last and final stage are those studies that are "Completed" already and have some results to report.

Ophthotech-Not Recruiting Print E-mail
This injectable therapy (E10030) is currently in a Phase 2b trial with 445 patients with wet macular degeneration.  It compares outcomes between patient groups receiving standard Lucentis treatment and those receiving Lucentis and E10030.  Lucentis blocks the substance called VEGF, which promotes the growth of blood vessels.  E10030 blocks a different substance, PDGF, that seems to contribute to wet AMD as well. The goal is to show that the combined therapy provides better results.  Results of the trial will be released in the first half of 2012.  For more information, visit Clinical Trials.gov or Ophthotech.
 
REDD14NP - Recruiting Print E-mail
REDD14NP– Quark
This Phase I study is recruiting patients with wet macular degeneration to receive a single injection of a drug designed to interfere with a gene that seems to be active in creating AMD.
Read more...
 
Sirolimus (Rapamycin) – Not Recruiting Print E-mail

Sirolimus (Rapamycin)

This is a randomized, multi-center study and is taking place throughout the United States. Sirolimus is designed to stop the growth of blood vessels in the macula.
Read more...
 
ATG003 Eye Drops - Recruiting Print E-mail
ATG003 Eye Drops
This study is investigating the use of an eye drop in patients who are already getting Lucentis or Avastin.
Read more...
 
CABERNET Radiation Implant-Phase 3 Results Print E-mail

Share Share CABERNET – Strontium-90 Beta Radiation Implant Trial

Results are now available for this Phase III trial.  After 2 years, the study could not show epiretinal brachytherapy to be "non-inferior" to Lucentis.  Noninferiority was the primary endpoint for the clinical trial.  Previous research had led to the hope that radiation treatment could be used with Lucentis to reduce the number of injections that were needed.  More research will be conducted, but these results are a set-back for this experimental treatment.  

Read more...
 
Radiation Therapy - Recruiting Print E-mail
Share Share Enrollment is underway for a clinical trial for the treatment of wet age-related macular degeneration (AMD). The trial is sponsored by Theragenics Corporation® and will investigate the safety and ability of using the TheraSightTM Ocular Brachytherapy System to treat wet AMD.
Read more...
 
COBALT Combination Therapy - Not Recruiting Print E-mail
Share Share COBALT – Bevasiranib & Lucentis Combination Therapy
A Phase III clinical trial is no longer recruiting patients to participate in a comparison study between Lucentis and Bevasiranib.  Opko Health, Inc.
Read more...
 
Potentia Pharmaceuticals – Recruiting Print E-mail
Share Share This Phase I study (called ASap) will provide safety and tolerability information on the complement inhibitor (POT-4) injected into the eyes of patients with wet AMD. Earlier animal studies showed no toxicity even when injected at high concentrations. Participants received a single injection of the drug, with some patients receiving higher doses than others. This is a one year study, but information from the early data is being released.
Read more...
 
Completed Clinical Trials Print E-mail
Here are some of the clinical trials that have been completed recently:
Read more...
 


2013hia_color
constanctcontact-allstar

Facebook_Badge

Search

Get News!

SIGN UP NOW

To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:

For Email Newsletters you can trust

Tell us...

Please tell us about yourself: